Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology, neurodegeneration, and Immunology. The company's products under development include Elepsia XR for the treatment of epilepsy; PDP-716 for the treatment of open-angle glaucoma; and Sezaby for the treatment of neonatal seizures. In addition, it is developing Vodobatinib (SCC-138), a c-ABL inhibitor, which is in phase 2 clinical trial to treat Parkinson's disease; has completed phase 1 clinical trial for the treatment of lewy body dementia; and in preclinical trial to treat alzheimer's disease. Further, the company develops Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia that is in phase 2 clinical trial; and Vibozilimod (SCD-044), a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist, for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial. Additionally, it is developing SCD-153 for the treatment of alopecia areata and SBO-154, an anti-MUC-1 ADC, for the treatment of multiple tumors that is in preclinical trials. The company was incorporated in 2006 and is based in Mumbai, India.

Revenue projections:

Revenue projections for SPARC
Revenue projections for SPARC

Sun Pharma Advanced Research Company Limited's projected revenue growth suggests a favorable investment opportunity, particularly if confirmed by strong fundamental indicators. Investors might see the company's rising financial performance as a sign of future profitability and consider it a good time to invest in Sun Pharma Advanced Research Company Limited.

Financial Ratios:

currentRatio 2.470000
forwardPE 4.059927
debtToEquity 41.776000
earningsGrowth 0.000000
revenueGrowth 67.168000
grossMargins 0.397190
operatingMargins 0.955530
trailingEps 47.870000
forwardEps 55.400000

Sun Pharma Advanced Research Company Limited's current ratio is 2.47, showing the company's capacity to service its short-term debt through its cash reserves and current assets. This is a positive indicator of liquidity, suggesting Sun Pharma Advanced Research Company Limited has no trouble covering its short-term financial obligations.
Sun Pharma Advanced Research Company Limited's positive gross and operating margins indicate the company's ability to operate profitably. These margins reflect strong financial management, with efficient cost control contributing to sustained profitability and a solid financial outlook.
SPARC's forward EPS exceeding its trailing EPS implies that the company is projected to be more profitable this year. This suggests an improvement in financial performance, with analysts expecting SPARC to generate stronger earnings compared to the previous financial year.

Price projections:

Price projections for SPARC
Price projections for SPARC



Recommendation changes over time:

Recommendations trend for SPARC
Recommendations trend for SPARC


Analysts have maintained a buy bias for SPARC, which could prompt investors to consider the stock as a viable investment. With this positive outlook, SPARC is positioned as an attractive option for those looking to park their money in a stable and potentially lucrative company.